So/hl 51/>gsap dna/dna&rna
81455 identifies a targeted genomic sequencing panel for specified neoplasm types; G0452 reports the physician’s interpretation and report of molecular results.
CMS RVU26D · Effective 2026-10-01
Reports a physician’s interpretation of molecular pathology test results, separately from or as part of the global diagnostic service. Compare G0452 office and facility rates across CMS payment localities in Oklahoma.
Amounts below use the non-QP conversion factor for participating physicians. These are base physician payments before claim-level adjustments, not patient costs or total hospital charges.
Oklahoma has 1 payment locality in this comparison. Use the service location to choose the applicable amount. These are the supported base rates for the payment area shown below, using the same CMS release.
$44.93
1 of 1 localities have a supported rate.
Payment area: Oklahoma
One mapped payment locality.
No supported rate
These are locality ranges, not averages or address-specific quotes. A facility-setting amount covers the physician service; it does not include a hospital’s separate bill. Choose a locality below to inspect its calculation, compare other payment areas, or price a percentage of Medicare.
Molecular pathology
Reports a physician’s interpretation of molecular pathology test results, separately from or as part of the global diagnostic service.
A physician reviews results from a molecular pathology assay and prepares an interpretation and report. The testing may analyze DNA or RNA from sources such as tumor tissue or blood to identify molecular findings relevant to diagnosis or treatment. A pathologist or another qualified physician may provide this service in a hospital, reference laboratory, or other setting where molecular diagnostic testing is performed.
Report G0452 for the physician’s interpretive service when supported by the work documented; the assay itself is represented by its applicable test code. CMS recognizes professional and technical components: modifier 26 identifies the interpretation, and modifier TC identifies the technical work, including equipment and staff. Without either modifier, the claim represents the global service. Documentation should identify the test results reviewed and include the physician’s interpretive findings and report. The CMS file lists modifiers 26 and TC as separately priced.
163.3K
Medicare services in 2024 · #428 by national volume
This summary was written with AI assistance from CMS physician fee schedule data and checked against the CMS billing rules shown here. Rates on this page come directly from CMS files.
Office rates for Oklahoma, from the same CMS release.
So/hl 51/>gsap dna/dna&rna
81455 identifies a targeted genomic sequencing panel for specified neoplasm types; G0452 reports the physician’s interpretation and report of molecular results.
Unlisted molecular pathology
81479 represents an unlisted molecular pathology procedure when the assay lacks a specific code. G0452 represents interpretive work, not the assay procedure.
Hl neo gsap 5-50dna/dna&rna
81450 identifies genomic sequencing for hematolymphoid neoplasms. G0452 describes the physician’s interpretation and report rather than the sequencing assay.
Find the payment area for your service address, then open its rate page for calculation inputs, release history and the percentage-of-Medicare tool. A city may cross payment-area boundaries; the ZIP lookup above helps resolve the location.
1 of 1 payment localities
Office / nonfacility
$44.93
Facility
Unavailable
Fee-sheet and API access are in early access. Tell us which codes and locations your team needs.
Each RVU component is multiplied by its own geographic practice cost index (GPCI). The three adjusted components are added, then multiplied by the conversion factor. These are the inputs used for G0452 in Oklahoma.
PPRRVU2026_Oct_nonQPP.csv
15,270
GPCI2026.csv
86
| Component | RVU | Locality factor | Adjusted |
|---|---|---|---|
| Physician work | 0.91 | × 1.000 | 0.9100 |
| Practice expense | 0.47 | × 0.893 | 0.4197 |
| Malpractice | 0.02 | × 0.777 | 0.0155 |
| Total RVUs | 1.3453 | ||
| Conversion factor | × 33.4009 | ||
Office / nonfacility rate, Oklahoma$44.93
| Component | RVU | Local GPCI |
|---|---|---|
| Work | 0.91 | 1 |
| Practice expense | 0.47 | 0.893 |
| Malpractice | 0.02 | 0.777 |
(0.91 × 1 + 0.47 × 0.893 + 0.02 × 0.777) × $33.4009 = $44.93
The office and facility calculations use their respective practice-expense RVUs. The facility amount here is the physician fee, not a separate hospital or facility bill.
G0452 represents the physician’s interpretation and report, not the laboratory procedure that generates the molecular results. Report the applicable assay code for the testing itself.
Modifier 26 reports the professional interpretation, while modifier TC reports the technical work, including equipment and staff. Without a modifier, G0452 represents the global service.
Document the molecular test results reviewed and the physician’s interpretation and report. The record should make clear that the reported service includes interpretive work, not only test performance.
Yes, the interpretation may be reported with the applicable molecular assay code when both the test and the physician’s interpretive service are furnished and documented.
No. G0452 identifies the interpretation and report service; the assay code identifies the specific molecular test and its scope.
FeeBase calculates base physician payments from CMS work, practice-expense, and malpractice RVUs, adjusted by each locality’s geographic indices and the applicable conversion factor. Unavailable or separately priced services are labeled rather than assigned a made-up amount.
Source: RVU26D. Effective 2026-10-01 through the day before 2027-01-01.